Gustavo Rodriguez (@JGCardio) header
Gustavo Rodriguez (@JGCardio) profile picture

Cardiólogo clínico y ecocardiografista de adultos.

Joined August 2017
Photo by Gustavo Rodriguez (@JGCardio)Photo by Gustavo Rodriguez (@JGCardio)Photo by Gustavo Rodriguez (@JGCardio)Photo by Gustavo Rodriguez (@JGCardio)Photo by Gustavo Rodriguez (@JGCardio)Photo by Gustavo Rodriguez (@JGCardio)Photo by Gustavo Rodriguez (@JGCardio)Photo by Gustavo Rodriguez (@JGCardio)Photo by Gustavo Rodriguez (@JGCardio)Photo by Gustavo Rodriguez (@JGCardio)
Preoperative medicine is not “medical clearance”: it is risk modification Surgery challenges physiological reserve. Anesthetic-induced vasodilation, blood loss, fluid shifts, inflammation and postoperative immobility can expose cardiovascular, respiratory or metabolic vulnerabilities that remain compensated in daily life. The question before surgery is not simply whether a patient is “fit,” but which risks are modifiable and which outcomes matter to the patient. In this review, Irizarry-Alvarado and colleagues challenge the ritual of preoperative clearance. They advocate a stepwise assessment anchored in symptoms, comorbid disease, medications, procedural risk and shared decision-making. More testing does not necessarily mean safer surgery. Routine laboratory panels, electrocardiography, chest radiography and ischemia testing in stable, low-risk patients can generate incidental findings, delays and downstream procedures without changing management. New exertional dyspnea, decompensated heart failure, significant valvular disease or declining exercise tolerance, by contrast, demand focused evaluation because they may signal inadequate reserve. Medication reconciliation is an intervention, not clerical work. SGLT2 inhibitors may increase perioperative ketoacidosis risk during fasting, anticoagulant interruption requires balancing bleeding against thrombosis, and GLP-1 receptor agonists prompt individualized aspiration-risk assessment. These decisions must account for the procedure and the patient rather than follow automatic rules. Importantly, frailty and baseline cognition can predict vulnerability that age alone misses. Functional decline, delirium and loss of independence may matter as much as traditional cardiopulmonary complications. Prehabilitation, nutrition, anemia management and postoperative support should enter the discussion before the operating room. This is a guideline-informed narrative review, not a trial demonstrating that any single assessment strategy improves survival. Its value is a change in clinical reasoning: avoid low-value rituals, identify actionable physiology and coordinate care. A useful preoperative consultation does not certify the absence of risk. It turns recognized risk into a plan. Reference 📚 Irizarry-Alvarado et al. 2026. JAMA Internal Medicine. doi.org/10.1001/jamainternme… #PerioperativeMedicine #Anesthesiology #PatientSafety #ClinicalReasoning #EvidenceBasedMedicine
2
73
1
208
9,452
🫀 Tricuspid regurgitation is no longer the “forgotten” valve—but when is the right time to intervene? A review of the 2025 ESC/EACTS update explores imaging, patient selection, and surgical and transcatheter treatment options. 🔗 imrpress.com/journal/RCM/27/… #TricuspidRegurgitation #Cardiology #StructuralHeart
1
10
3
50
2,639
Gustavo Rodriguez retweeted
Bioprosthetic valve dysfunction (BVD), hemodynamic valve dysfunction (HVD), and bioprosthetic valve failure (BVF): they may sound synonymous, but they are not. I tried to clarify the differences. The discussion also brought back the valve durability clock, which divided the panel. Some argued that it is not a major concern: we intervene earlier because intervention will eventually be necessary anyway. I somewhat disagree. To me, this is a conceptual and, to some extent, an ethical issue, particularly since we are not talking about a demonstrated mortality benefit of early intervention over clinical surveillance. Symptoms will eventually develop, but how soon? Moderate stenosis will eventually progress to severe stenosis, but over what timeframe? Intervening 1–2 years earlier in a patient whose life expectancy is shorter than the valve’s remaining durability is one thing. Intervening 5–6 years earlier in a patient who is likely to outlive the valve is quite another. In the latter scenario, I believe we should seriously question whether early intervention is preferable to clinical surveillance. Perhaps it is time to revisit the natural history studies of aortic stenosis, which certainly exist, to better understand the time course of progression from, e.g., moderate to severe stenosis, and from an asymptomatic state to the development of symptoms. #TCT2026
2
24
89
6,713
🫀 New review on tricuspid regurgitation! 🔹Phenotype & RV–PA coupling 🔹Patient selection & timing 🔹Residual TR matters 👏 Congrats to Javier Solsona, @iLauraGG & our Vall d’Hebron team! 📖 Read the paper: mdpi.com/2077-0383/15/21/858… @vallhebron @VHIR_ @cardioimagenVH
41
121
6,045
Gustavo Rodriguez retweeted
Deprescripción cardiovascular en el paciente mayor frágil: qué retirar, en qué orden y qué no tocar sin cardiología La píldora reúne lo que dicen la guía ESC 2024 de hipertensión, los criterios STOPP/START versión 3 y el estudio OPTIMISE sobre la retirada de fármacos cardiovasculares en el paciente mayor frágil. Incluye una tabla fármaco por fármaco, el orden de la retirada y los tratamientos que no se suspenden sin consultar con cardiología. cardioteca.com/cardiologia-c… 🩺 La guía ESC 2024 de hipertensión pide cribar la fragilidad con pruebas validadas y admite retirar antihipertensivos cuando la presión baja al avanzar la fragilidad. 📉 En el estudio OPTIMISE, con 569 pacientes de 80 años o más, retirar un antihipertensivo mantuvo la presión sistólica por debajo de 150 mmHg en el 86% frente al 88% con el tratamiento habitual. 💊 Los criterios STOPP/START versión 3 señalan el ácido acetilsalicílico en prevención primaria y la estatina en prevención primaria a partir de los 85 años con fragilidad establecida y esperanza de vida menor de 3 años. 🫀 La antiagregación tras un stent reciente, el tratamiento de la insuficiencia cardiaca con FEVI reducida y la anticoagulación con una prótesis mecánica no se retiran sin hablarlo con cardiología.
27
1
71
3,724
🫀 Can coronary atherosclerosis actually regress? Our new randomized FLOWPROMOTE trial analysis, published TODAY in JAMA Cardiology, shows remarkable coronary plaque regression with intensive LDL-C lowering! Atherosclerosis is not necessarily a one-way process. 📄 JAMA Cardiology: doi.org/10.1001/jamacardio.2… #Atherosclerosis #LDL #Cardiology #CCTA
79
383
58
1,390
262,780
Gustavo Rodriguez retweeted
Cómo ajustar la dosis de acenocumarol y warfarina según el INR: tabla, reparto semanal y vitamina K La píldora explica cómo modificar la dosis total semanal de acenocumarol y warfarina según el INR, cómo repartirla en comprimidos y cuándo repetir el control. Recoge la tabla de ajuste de la CAMFiC, las pautas de vitamina K de la ficha técnica y cuatro casos resueltos. cardioteca.com/cardiologia-c… 📊 El ajuste se hace sobre la dosis total semanal: en la tabla de la CAMFiC, un 10% con INR de 1,5 a 1,7 o de 3,3 a 4,9 y un 20% con INR menor de 1,5. ⚖️ Con un INR aislado a 0,5 o menos del rango en un paciente estable, la guía ACCP sugiere mantener la dosis y repetir el control en 1 a 2 semanas. 💊 Con acenocumarol e INR de 4,5 a 10 sin sangrado, la ficha técnica indica interrumpir el tratamiento sin vitamina K; por encima de 10, de 1 a 5 mg por vía oral. 🔁 Con un tiempo en rango inferior al 70%, la guía ESC 2024 recomienda pasar a un anticoagulante oral directo si no hay contraindicación.
42
1
123
7,459
Gustavo Rodriguez retweeted
Updated intro2echo.com with sections on structural heart echo. Walks through the steps for TAVR, mTEER, and tTEER. This includes 3D models as well as simulated 2D ultrasound images. Would appreciate feedback and suggestions for improvement! intro2echo.com/#mteer
6
50
3
258
17,097
Gustavo Rodriguez retweeted
🫀From Healthy Atria to Atrial Failure: Rethinking Atrial Cardiomyopathy (AtCM) from the #HFA_ESC clinical consensus statement: 📍AtCM extends beyond #AF: Electrical, mechanical & structural abnormalities may precede clinically apparent AF or #HeartFailure 📍Diagnosis: Electrical atrial dysfunction (P-wave score ≥1) PLUS ≥1 of: mechanical dysfunction, atrial enlargement or excessive atrial fibrosis 📍Proposed diagnostic thresholds: - P-wave ≥120 ms (standard ECG) or ≥150 ms (amplified ECG) - Advanced interatrial block: P-wave ≥120 ms + biphasic morphology in ≥2 inferior leads - LA reservoir strain <23% - LAVi >40 mL/m² (>48 mL/m² in women >65 years) - Atrial fibrosis: thresholds pending validation 📍New P-wave scoring system (0–4): Ranges from normal P-wave (0), prolonged P-wave (1), advanced interatrial block without (2) or with paroxysmal arrhythmia (3), to persistent atrial arrhythmia (4). 📍Atrial failure: End-stage AtCM, characterized by persistent AF or HF with symptoms attributable to atrial disease. 📍Early recognition matters! Risk factor & comorbidity management may help prevent or delay progression to atrial failure. Read more in #EJHF @EJHFEiC 🔗 doi.org/10.1002/ejhf.3782 @escardio @h_arfsten @GTersalvi @jozinetm
69
1
178
12,883
Gustavo Rodriguez retweeted
A defining study on evaluating MR with Echocardiography & impact on @ASE360 Guidelines. @ACCinTouch @SCMRorg
🎯 Less is more in mitral regurgitation assessment In 177 patients undergoing near-simultaneous Echo & CMR, just 2 ASE criteria identified significant MR with 91–95% specificity. 🫀 Smarter integration, less quantification, greater diagnostic confidence doi.org/10.1016/j.jcmg.2026.…
1
19
63
5,120
Gustavo Rodriguez retweeted
Sharing here the #LAAO #LAAC simulator laa.liorjankelson.com. See the left atrial appendage with 3D CT correlation, explore LAAOD positioning, play with device alignment, see "shoulders" and leaks in each view and more. #eppeeps #afib
2
43
1
224
11,831
Gustavo Rodriguez retweeted
ECG patterns suggestive of left main disease. Pay close attention to lead aVR.
39
174
8,062
Gustavo Rodriguez retweeted
🫀 Are we measuring pericardial effusions the wrong way? We routinely classify pericardial effusions as small, moderate, or large based on linear measurements. But does a single measurement in millimeters accurately represent the actual volume of pericardial fluid? Study in @JournalASEcho challenges this onlinejase.com/article/S0894… 🔬 245 patients undergoing pericardiocentesis Median drained volume: 500 mL (range 50–4,300 mL) 76.7% had cardiac tamponade Actual drained volume served as the reference standard. 📊 How did different echo methods perform? Between end diastolic thickness, plax and PSAx area- apical 4 chamber Simpson’s volumetric estimation performed the best ✅ Accuracy: 80.4% vs 49.4% Perhaps it is time to rethink how we quantify pericardial effusions! 💡 if volumetric assessment is substantially more accurate, should we move from millimeters to milliliters in routine echocardiography? And more importantly, would this change clinical decision-making—or simply improve the precision of our reports? #EchoFirst #CardioTwitter #CVImaging
4
62
1
175
10,661
Gustavo Rodriguez retweeted
Guarda esta imagen, luego me agradeces. Si un paciente con FA presenta un ACVi mientras recibe anticoagulación, el riesgo de transformación hemorrágica obliga a suspenderla. La pregunta de siempre es: ¿cuándo reiniciarla? Esta gráfica ayuda a responderlo y, en general, favorece el reinicio durante la primera semana especialmente si no existe transformación hemorrágica o no es extensa la isquemia.
5
132
2
409
16,958
Gustavo Rodriguez retweeted
🧵 PREECLAMPSIA 2026 | Lo que ha cambiado y debes recordar La última revisión de The Lancet actualiza diagnóstico, prevención y tratamiento. Varias ideas clásicas han quedado atrás 👇
1
128
385
10,717
Gustavo Rodriguez retweeted
🥁Trabajo imperdible y necesario¡¡¡ bit.ly/4nxvMU8 🚩Nuevo algoritmo para estimar las presiónes de llenado con Ecocardio: ➡️Reduce significativamente los casos indeterminados. ➡️Mejora la precisión para identificar presión de llenado elevada, especialmente en pacientes con FEVI normal. ➡️Combinado con péptidos natriuréticos, mejora la identificación de insuficiencia cardíaca.
59
201
12,286
Gustavo Rodriguez retweeted
Nuevo consenso sobre la Hipertensión Resistente Integra al abordaje el acrónimo RESIST para el diagnóstico, manejo y envío con especialistas Am Coll Cardiol 2026 10.1016/j.jacc.2026.08.028
1
139
410
13,246
Gustavo Rodriguez retweeted
Revascularization of #CAD in #HeartFailure: who, when, & how? This #EJHF Expert Consensus Statement proposes a practical, symptom-based approach: 📍Start with the symptoms: are they predominantly HF-related or angina-related?
📍Optimize GDMT first in all patients with HF, & also assess for eligibility for CRT +/- invasive procedures (eg M-TEER, VAD)
📍Persistent angina despite GDMT? Consider revascularization, with assessment of coronary anatomy, ischaemia & viability where appropriate.
📍CABG or PCI? Consider surgical risk & coronary complexity, with PCI an option in patients at higher surgical risk or with less complex coronary disease.
📍Heart Team discussion is key to individualized decision-making. 📖 Read the full paper: doi.org/10.1093/ejhf/xuag230 @EJHFEiC @escardio #HFA_ESC
20
2
52
2,611
🧵 Hilo 1/2 🚨 NUEVO consenso ADA/EASD 2026 en #DM2 Cambio de paradigma 👇 ❌ Solo HbA1c ✅ Peso y obesidad ❤️ Protección CV 🫘 Protección renal 🫀 IC 🧬 MASLD y multimorbilidad 🎯 Objetivo: tratar al paciente, no solo la glucosa🔄
3
66
1
170
5,811
Gustavo Rodriguez retweeted
Fantastic educational work.😍😍
In this #3D TEE mid-esophageal RV in-out view you can better understand the location of different types of VSD in echo #echofirst supracristal VSD lying more cranial than the infracristal. 👉 for more morphological details check this out doi.org/10.1016/j.athoracsur…
1
20
144
13,572